机构：[1]Department of Neurology, University Hospital Bonn, Bonn, Germany[2]Department of Neurology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands[3]Department of Neuroradiology, University Hospital Bonn, Bonn, Germany[4]Department of Neurology, Ulm University Hospital, Ulm, Germany[5]Department of Neuroscience, IRCCS Ospedale Policlinico San Martino, Genoa, Italy[6]Division of Neurology, University of Alberta Hospital, Edmonton, AB, Canada[7]Department of Neurology, Royal Adelaide Hospital, Adelaide, SA, Australia[8]Univ. Lille, Inserm, CHU Lille, U1172 – LilNCog – Lille Neuroscience & Cognition, Lille, France[9]Vancouver Stroke Program, Division of Neurology, University of British Columbia, Vancouver, BC, Canada[10]Department of Neurology and Emergency, Xuanwu Hospital, Capital Medical University, Beijing, China神经科系统内科系统神经内科急诊科首都医科大学宣武医院[11]Department of Neurology, Saudi German Hospital, Jeddah, Saudi Arabia[12]Department of Neurology, John Hunter Hospital, Newcastle, NSW, Australia[13]Division of Neurology, McGill University Health Centre, Montreal, QC, Canada[14]Department of Neurology, Hospital Complex of Toledo, Toledo, Spain[15]Department of Neurology, University of Leipzig, Leipzig, Germany[16]Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany[17]Department of Neurology, Klinikum Ludwigshafen, Ludwigshafen, Germany[18]Neuroradiology Unit, Azienda Ospedaliera Consorziale Policlinico di Bari, Italy[19]Department of Neurology, Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse, Toulouse, France and Inserm, Toulouse NeuroImaging Center, Université de Toulouse, Toulouse, France[20]Department of Neurology, Oslo University Hospital, Oslo, Norway[21]Neurology Unit, Department of Neurological Sciences, Christian Medical College and Hospital, Vellore, Tamil Nadu, India[22]CEEM and Institute of Anatomy, Faculty of Medicine, University of Lisbon, Lisbon, Portugal[23]Stroke Centre, Lisbon Central University Hospital, Lisbon, Portugal[24]Department of Neurology, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden[25]Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden[26]Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland[27]Department of Neurology & Stroke, Eberhard-Karls University, Tuebingen, Germany and Hertie Institute for Clinical Brain Research, EberhardKarls University, Tuebingen, Germany[28]Instituto Nacional de Neurologia y Neurocirugia, Mexico City, Mexico[29]Hospital das Clinicas/São Paulo University and Hospital Israelita Albert Einstein, São Paulo, Brazil[30]Department of Neurology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland[31]Department of Neurology, Jena University Hospital, Jena, Germany[32]Centro de Estudas Egas Moniz, Faculdade de Medicina, Universidade de Lisboa, Portugal
There is little data on the role of endovascular treatment (EVT) of cerebral venous sinus thrombosis (CVST) due to vaccine-induced immune thrombotic thrombocytopenia (VITT). Here, we describe clinical characteristics and outcomes of CVST-VITT patients who were treated with EVT.We report data from an international registry of patients who developed CVST within 28 days of SARS-CoV-2 vaccination, reported between 29 March 2021 and 6 March 2023. VITT was defined according to the Pavord criteria.EVT was performed in 18/136 (13%) patients with CVST-VITT (92% aspiration and/or stent retrieval, 8% local thrombolysis). Most common indications were extensive thrombosis and clinical or radiological deterioration. Compared to non-EVT patients, those receiving EVT had a higher median thrombus load (4.5 vs 3). Following EVT, local blood flow was improved in 83% (10/12, 95% confidence interval [CI] 54-96). One (6%) asymptomatic sinus perforation occurred. Eight (44%) patients treated with EVT also underwent decompressive surgery. Mortality was 50% (9/18, 95% CI 29-71) and 88% (8/9, 95% CI 25-66) of surviving EVT patients achieved functional independence with a modified Rankin Scale score of 0-2 at follow-up. In multivariable analysis, EVT was not associated with increased mortality (adjusted odds ratio, 0.66, 95% CI 0.16-2.58).We describe the largest cohort of CVST-VITT patients receiving EVT. Half of the patients receiving EVT died during hospital admission, but most survivors achieved functional independence.
第一作者机构：[1]Department of Neurology, University Hospital Bonn, Bonn, Germany[*1]Department of Neurology, University Hospital Bonn, Venusberg-Campus 1, Bonn, Nordrhein-Westfalen 53127, Germany.
共同第一作者：
通讯作者：
通讯机构：[1]Department of Neurology, University Hospital Bonn, Bonn, Germany[*1]Department of Neurology, University Hospital Bonn, Venusberg-Campus 1, Bonn, Nordrhein-Westfalen 53127, Germany.
推荐引用方式(GB/T 7714)：
Johannes Weller,Katarzyna Krzywicka,Anita van de Munckhof,et al.Endovascular treatment of cerebral sinus thrombosis due to vaccine-induced immune thrombotic thrombocytopenia[J].EUROPEAN STROKE JOURNAL.2024,9(1):105-113.doi:10.1177/23969873231202363.
APA：
Johannes Weller,Katarzyna Krzywicka,Anita van de Munckhof,Franziska Dorn,Katharina Althaus...&José M Ferro.(2024).Endovascular treatment of cerebral sinus thrombosis due to vaccine-induced immune thrombotic thrombocytopenia.EUROPEAN STROKE JOURNAL,9,(1)
MLA：
Johannes Weller,et al."Endovascular treatment of cerebral sinus thrombosis due to vaccine-induced immune thrombotic thrombocytopenia".EUROPEAN STROKE JOURNAL 9..1(2024):105-113
